[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356214-105":59,"doc-detail-356214-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","e7389-lf-as-a-first-line-chemotherapy-results-from-the-phase-1-dose-expansion-part-of-study-114","E7389-LF as a first-line chemotherapy - results from the phase 1 dose-expansion part of study 114","","Ongoing need for first-line (1L) chemotherapy in metastatic/advanced HER2-negative breast cancer led to this phase 1 dose-expansion evaluation of E7389-LF in Study 114. Japanese adults with confirmed HER2-0 or HER2-low disease, including luminal-like and triple-negative tumors, received E7389-LF without prior advanced/metastatic chemotherapy. Safety and efficacy were assessed by RECIST v1.1, alongside investigator tumor review and biomarker changes. Among 26 treated patients, common TRAEs included alopecia, neutropenia, and thrombocytopenia; no complete responses occurred and partial responses yielded an ORR of 30.8%. Median PFS was 8.1 months overall, with vasculature- and IFNγ-related biomarker changes observed across treated patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/e7389-lf-as-a-first-line-chemotherapy-results-from-the-phase-1-dose-expansion-part-of-study-114/356214/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/e7389-lf-as-a-first-line-chemotherapy-results-from-the-phase-1-dose-expansion-part-of-study-114/356214.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient population was included in the phase 1 dose-expansion study 114?","Question",{"text":112,"@type":113},"Japanese patients (≥20 years) with confirmed HER2-negative breast cancer (HER2-0 or HER2-low) were enrolled. Subgroup analyses included luminal-like and triple-negative tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the main findings on efficacy for E7389-LF as a 1L chemotherapy?",{"text":117,"@type":113},"No complete responses were observed, and confirmed partial responses produced an objective response rate of 30.8%. Median progression-free survival was 8.1 months overall, and median overall survival was not reached at 22.7 months follow-up.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety outcomes were reported for patients receiving E7389-LF?",{"text":121,"@type":113},"Most patients discontinued treatment by the data cutoff, and common treatment-related adverse events included alopecia, neutropenia, and thrombocytopenia. Three patients discontinued due to treatment-related adverse events.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356214,1790167385,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Ishiguro etal. Breast Cancer Research (2026) 28:158 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02295-8](https://doi.org/10.1186/s13058-026-02295-8)  \nRESEARCH Open Access  \nE7389-LF as a first-line chemotherapy  for patients with metastatic/advanced HER2-negative breast cancer: results from the phase  \n1 dose-expansion part of study 114  \nHiroshi Ishiguro 1*, Yasuo Miyoshi2, Hiroyuki Yasojima3, Junichiro Watanabe4, Toshimi Takano5, Akihiko Shimomura6, Eriko Tokunaga7, Toru Mukohara8, Yasuto Naoi9, Daiko Matsuoka10, Shiori Okumura10, Yohei Otake11, Takuya Suzuki10, Takao Takase12, Taro Semba13, Ziming Zhao14 and KanYonemori15  \nAbstract  \nBackground There is an ongoing need for first-line (1L) chemotherapies for metastatic HER2-negative breast cancer. This study evaluated the efficacy and safety profile of the dose-expansion part 6 of Study 114 in patients receiving E7389-LF as a 1L chemotherapy for metastatic/advanced HER2-negative breast cancer.  \nMethods Japanese patients (≥ 20 years of age) with confirmed HER2-negative breast cancer (HER2-0 or HER2-low) were enrolled; subgroup analyses included luminal-like and triple-negative breast cancer tumors. Eligible patients had ≥ 1 measurable lesion per Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST v1 . 1) and had not received prior chemotherapy for advanced/metastatic disease. Objectives included safety, efficacy, and biomarker changes. Tumors were assessed by investigators per RECIST v1 .1.  \nResults Twenty-six patients received E7389-LF. Overall, 24 patients (92 . 3%) had discontinued treatment by the data cutoff date (October 18, 2023) . Most common treatment-related adverse events (TRAEs) of any grade were alopecia (88 . 5%), neutropenia (88 . 5%; grade ≥ 3, 76. 9%), and thrombocytopenia (84 . 6%; grade ≥ 3, 34 . 6%) . Three patients discontinued due to TRAEs. No patient showed a complete response, and 8 (30 . 8%) had confirmed partial responses, for an objective response rate of 30. 8% . Median progression-free survival (PFS) was 8.1 months overall (patients with luminal breast cancer [n = 22]: 8.1 months; triple-negative breast cancer [n = 4]: 9.8 months) . Median overall survival was not reached at 22.7 months of follow-up. Median PFS on next-line therapy was 20.6 months. Changes in vasculature-and IFNγ-related biomarkers were observed in all patients who received E7389-LF.  \nConclusions These results highlight the antitumor activity and manageable safety profile of E7389-LF, indicating the potential of E7389-LF as a 1L treatment for patients with HER2-negative breast cancer, warranting further study. Clinical trials registration NCT03207672 . Registered 5 July 2017.  \nKeywords Eribulin, Liposome, E7389-LF, Metastatic/advanced breast cancer  \n*Correspondence:  \nHiroshi Ishiguro[ishiguro@saitama-med.ac.jp](ishiguro@saitama-med.ac.jp)  \nFull list of author information is available at the end of the article  \n© Eisai Inc. and the Authors 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/","cbCaijpcmvGwkXyL","https://ap.wps.com/l/cbCaijpcmvGwkXyL","pdf",2404228,13,"English","# Abstract\n# Background\n# Methods\n## Study population and eligibility\n## Objectives and assessments\n# Results\n## Treatment discontinuation and TRAEs\n## Tumor response and survival outcomes\n## Biomarker changes\n# Conclusions\n# Introduction","[{\"question\":\"What patient population was included in the phase 1 dose-expansion study 114?\",\"answer\":\"Japanese patients (≥20 years) with confirmed HER2-negative breast cancer (HER2-0 or HER2-low) were enrolled. Subgroup analyses included luminal-like and triple-negative tumors.\"},{\"question\":\"What were the main findings on efficacy for E7389-LF as a 1L chemotherapy?\",\"answer\":\"No complete responses were observed, and confirmed partial responses produced an objective response rate of 30.8%. Median progression-free survival was 8.1 months overall, and median overall survival was not reached at 22.7 months follow-up.\"},{\"question\":\"What safety outcomes were reported for patients receiving E7389-LF?\",\"answer\":\"Most patients discontinued treatment by the data cutoff, and common treatment-related adverse events included alopecia, neutropenia, and thrombocytopenia. Three patients discontinued due to treatment-related adverse events.\"}]","E7389-LF as a first-line chemotherapy - results from the phase 1 dose-expansion part of study 114 | PDF",1790124101,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2dd6b59d538e38cf142accb8f3e9975.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99e73eda714e200611430978d74dbdc1.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e720255eb96d733830441dd3a1f57f2.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/363df2a22434b42e29b64656dc082bd8.webp",980,1306]